In this study, we looked for head-to-head trials and NMAs that compared different LAMA/LABA FDC drugs for people with moderate-to-very severe COPD. A network meta-analysis (NMA) is another way to compare two or more different drugs when head-to-head trials have not been done. However, there are not many head-to-head trials that have compared different LAMA/LABA FDCs. Head-to-head clinical trials are the best way to compare two different drugs. Combining two bronchodilators in one inhaler (known as a long-acting muscarinic antagonist/long-acting β 2-agonist fixed-dose combination ) may be given to treat symptoms and stop flare-ups (‘exacerbations’) of COPD. Although the scope of each NMA varied, all five concluded that LAMA/LABA FDCs were generally comparable in terms of lung function improvements, patient-reported outcomes, and safety (where assessed).īronchodilators are medicines given to patients with COPD to help them breathe more easily. Indirect comparisons: Six NMAs were identified that reported indirect comparisons between LAMA/LABA FDCs five of these were within the pre-defined scope of this review. However, the differences in study methodology and patient characteristics between these studies made it difficult to draw generalizable conclusions regarding the comparative effectiveness of LAMA/LABA FDCs from the direct comparisons alone. While some differences in lung function outcomes were noted, where assessed, LAMA/LABA FDCs had comparable efficacy in improving symptoms, health status, exacerbations, and comparable safety profiles. Guideline on the clinical investigation of medicinal products for the treatment of chronic obstructive pulmonary disease (COPD) 2012.ĭirect comparisons: Four RCTs that provided head-to-head comparisons of LAMA/LABA FDCs were identified, and these varied in their study design, included patient population and reported endpoints. Spiolto Respimat summary of product characteristics 2019.īevespi Aerosphere™ prescribing information 2019.
Boehringer Ingelheim International GmbH.Ultibro Breezhaler summary of product characteristics 2017. Anoro Ellipta summary of product characteristics 2019.ĭuaklir Genuair summary of product characteristics 2017. 2020 report: global strategy for the diagnosis, management and prevention of COPD 2020. Global Initiative for Chronic Obstructive Lung Disease.Chronic obstructive pulmonary disease (COPD) fact sheet 2017.Īvailable from: (copd).
0 kommentar(er)
